The Company

Sentinel Oncology was founded at the beginning of 2005 by Bob Boyle, Stuart Travers and Gavin Simpson. In March 2006 Sentinel received investment from the Cambridge University Challenge fund and at the same time appointed Professor Ashok Venkitaraman to the board of Sentinel Oncology as a non-Executive Director.

Further funding from the Wellcome Trust as part of their "Seeding Drug Discovery" initiative was received during 2007.

Developing small molecule inhibitors

Sentinel has built a pipeline of small molecules designed to target hallmarks of solid tumours. In particular Sentinel is developing small molecule inhibitors that are activated selectively under tumour Hypoxia (the low oxygen environment found in all solid tumours).

Our vision is to develop drugs in oncology that are void of the systemic toxicities often associated with chemotherapeutics.